Rhelion Life Sciences' subsidiary Filament Health has signed a supply and licensing agreement with the University of Southern California to provide PEX010, a patented botanical psilocybin drug candidate, for a clinical study on Psilocybin Assisted Mindfulness Therapy targeting depression. This deal highlights Filament's role as a leading supplier of pharmaceutical-grade natural psilocybin, supporting over 80 research studies globally. The study aims to explore whether mindfulness meditation can enhance psilocybin therapy's effectiveness. Rhelion acquired Filament Health earlier in 2026, gaining its patents and drug candidates, positioning the company strongly in the psychedelic drug development sector.
Rhelion Life Sciences' subsidiary Filament Health's recent agreement with the University of Southern California for a psilocybin drug study provides context for health sector trading. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 19:14 WIB: of 91 priced US health stocks, 28 rose and 59 fell. Notable prices include TWST at USD 133.00 with a 1-day change of -1.30%, FLNA at USD 0.73 up 1.28%, and ALC at USD 66.90 down 1.24%.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
